PRZOOM - /newswire/ -
Elmsford, NY, United States, 2019/02/01 - International technology group SCHOTT is introducing SCHOTT TOPPAC® cosmetic, a new COC (cyclic olefin copolymer) polymer syringe specifically designed for cosmetic and medical applications involving hyaluronic acid - SCHOTT.com.
Thanks to a reduced needle pop-off risk, improved dose accuracy and high break resistance, the syringes are especially suitable for highly viscous drugs. The new polymer syringes will become available in February 2019 and will be displayed at IMCAS World Congress in Paris, Jan. 31 to Feb. 2, at TSK Laboratory’s booth #46.
Highly viscous formulations require the user to apply a great amount of force when injecting the gel, leading to discomfort or pain for the patient. In extreme cases, the applied strength can even result in needle pop-off, when the needle hub is disconnected from the syringe.
To ensure a safe and easy administration, SCHOTT TOPPAC® cosmetic syringes feature an integrated luer lock for a secure needle attachment and are compatible with most of the common needles on the market. A study conducted by SCHOTT found that the combination of the new syringe and the STERiJECT needle with HPC hub from TSK Laboratory, a leading manufacturer of needles for dermal fillers, showed superior results with an improved injection performance. Moreover, thanks to a reduced inner diameter of the barrel, the syringe system enables optimized extrusion forces and an improved dose accuracy. As part of the complete syringe system offering, the syringes are equipped with ergonomic container components to further simplify and relieve the injection process. The new syringes, which are made of COC, an advanced cyclic olefin copolymer of the highest purity, come with a 1ml filling volume in a ready-to-use format and are manufactured in fully integrated clean rooms equipped with state-of-the-art production technology.
“The highly viscous hyaluronic acid falls into the category of dermal fillers and is used to restore facial volume,” explains Tom van Ginneken, Global Product Manager SCHOTT TOPPAC® syringes. “Hence, the new syringes were primarily developed for the cosmetic market, which has recently seen a double digit growth rate”. The market growth is also reflected in the company’s investment in its polymer container production at its sites in Müllheim, Germany, and in St. Gallen, Switzerland.
SCHOTT has extensive expertise in manufacturing pharmaceutical packaging made out of polymer and this know-how was taken to develop the new SCHOTT TOPPAC® cosmetic syringes. The new syringes are part of the company’s broad portfolio of polymer and glass pharmaceutical containers, with SCHOTT TOPPAC® polymer syringes being commercially available in more than 90 countries.
SCHOTT (schott.com) is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products and intelligent solutions. SCHOTT is an innovative enabler for many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. With more than 15,500 employees at production sites and sales offices in 34 countries, the group has a global presence. In the 2017/2018 fiscal year, SCHOTT generated sales of 2.08 billion euros. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. This is one of the oldest private and one of the largest science-promoting foundations in Germany. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.